X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement includes funding for TriLink’s planned expansion of its nucleic acid production capabilities in San Diego, California. TriLink has experienced substantial demand for a wide range of nucleic acid products in support of multiple COVID-19 mRNA vaccine.
Lead Product(s): mRNA Covid-19 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 24, 2022
Details:
EyeGene expected to utilize TriLink’s CleanCap® technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials.
Lead Product(s): EG-COVID mRNA COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: EG-COVID
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: EyeGene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 04, 2021
Details:
The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to expand access to an mRNA Covid-19 vaccine in Thailand and other low-to-middle-income countries (LMICs) in Asia.
Lead Product(s): ChulaCov19 mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Chula - Cov19
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Chula Vaccine Research Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 02, 2021
Details:
Under this development partnership, TriLink will use its robust RNA manufacturing capabilities to respond to the global need for vaccine support against COVID-19.
Lead Product(s): Self-amplifying RNA vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Imperial College London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
